Research programme: Nitrogen oxide neutralisers - Medinox

Drug Profile

Research programme: Nitrogen oxide neutralisers - Medinox

Latest Information Update: 29 Jul 2011

Price : $50

At a glance

  • Originator Medinox
  • Class Thiocarbamates
  • Mechanism of Action Nitric oxide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 29 Jul 2011 No development reported - Preclinical for Type-2 diabetes mellitus in USA (PO)
  • 06 Aug 2003 This compound is still in active development
  • 12 Jun 2002 Phase-I clinical trial of NOX 700 in Type-2 diabetes mellitus in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top